Dyadic International (DYAI) Enterprise Value (2017 - 2026)
Dyadic International (DYAI) posted Enterprise Value of -$6.5 million for Q1 2026, up 23.8% sequentially from -$8.6 million in Q4 2025, and up 11.33% YoY from -$5.9 million in Q1 2025.
Dyadic International (DYAI) Enterprise Value (2017 - 2026) Analysis & Trends
Dyadic International has reported Enterprise Value for 10 years, with the latest figure at -$6.5 million in Q1 2026.
- Quarterly Enterprise Value rose 11.33% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.5 million (up 11.33% YoY) and the FY2025 annual result came in at -$8.6 million, up 7.68% from the prior year.
- Enterprise Value climbed to -$6.5 million in Q1 2026 per DYAI's latest filing, from -$8.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.2 million in Q3 2023 and troughed at -$4.1 billion in Q1 2022.
- A 5-year average of -$250.4 million and a median of -$9.3 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 26582.05% in 2022, then surged 99.71% in 2023.
- Over 5 years, Enterprise Value stood at -$12.6 million in 2022, then surged by 42.54% to -$7.3 million in 2023, then slipped by 27.54% to -$9.3 million in 2024, then advanced by 7.68% to -$8.6 million in 2025, then grew by 23.8% to -$6.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$6.5 million, -$8.6 million, and -$8.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | -7.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.52 Mn |
| Dec 31, 2025 | -8.55 Mn |
| Sep 30, 2025 | -8.93 Mn |
| Jun 30, 2025 | -9.04 Mn |
| Mar 31, 2025 | -7.35 Mn |
| Dec 31, 2024 | -9.26 Mn |
| Sep 30, 2024 | -9.92 Mn |
| Jun 30, 2024 | -10.10 Mn |
| Mar 31, 2024 | -12.04 Mn |
| Dec 31, 2023 | -7.26 Mn |
| Sep 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | -4.62 Mn |
| Mar 31, 2023 | -11.74 Mn |
| Dec 31, 2022 | -12.64 Mn |
| Sep 30, 2022 | -14.20 Mn |
| Jun 30, 2022 | -15.64 Mn |
| Mar 31, 2022 | -4.11 Bn |
| Dec 31, 2021 | -20.26 Mn |
| Sep 30, 2021 | -22.75 Mn |
| Jun 30, 2021 | -12.40 Mn |